{"id":18821,"date":"2026-07-27T13:00:22","date_gmt":"2026-07-27T08:00:22","guid":{"rendered":"https:\/\/usnews-14267fa.ingress-comporellon.ewp.live\/?p=18821"},"modified":"2026-07-27T13:00:22","modified_gmt":"2026-07-27T08:00:22","slug":"astrazeneca-maintains-outlook-as-cancer-rare-disease-drugs-drive-profit-beat","status":"publish","type":"post","link":"https:\/\/usnews-14267fa.ingress-comporellon.ewp.live\/?p=18821","title":{"rendered":"AstraZeneca maintains outlook as cancer, rare disease drugs drive profit beat"},"content":{"rendered":"<p><script>\r\n  atOptions = {\r\n    'key' : '644b717812d811d6a1c1fc5b6ccd6fa6',\r\n    'format' : 'iframe',\r\n    'height' : 90,\r\n    'width' : 728,\r\n    'params' : {}\r\n  };\r\n<\/script>\r\n<script src=\"https:\/\/www.highperformanceformat.com\/644b717812d811d6a1c1fc5b6ccd6fa6\/invoke.js\"><\/script>\r\n<br \/>\n<\/p>\n<div>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><!-- HTML_TAG_START -->July 27 (Reuters) &#8211; AstraZeneca backed its annual and long-term forecasts on Monday after topping second-quarter profit expectations on demand for its cancer and rare disease \u200ctherapies, as the drugmaker sought to quell concerns after recent trial setbacks.<!-- HTML_TAG_END -->  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><!-- HTML_TAG_START -->Although strong \u200cdemand continues to drive growth against a background of broader pricing pressures, an unexpected trial failure this month \u200bhas turned attention to AstraZeneca&#8217;s drug pipeline and whether its longer-term revenue target could be under threat.<!-- HTML_TAG_END -->  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><!-- HTML_TAG_START -->The company separately detailed the outcome of a successful late-stage gastric cancer trial, while another study of its rare-disease drug ultomiris failed to meet the primary goal of a study \u200cin patients with a life-threatening \u2060complication from stem-cell transplants.<!-- HTML_TAG_END -->  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><!-- HTML_TAG_START -->AstraZeneca shares were up 1.6% in early trading.<!-- HTML_TAG_END -->  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><!-- HTML_TAG_START -->PHARMACEUTICAL DIVERSITY<!-- HTML_TAG_END -->  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><!-- HTML_TAG_START -->The pharmaceutical giant&#8217;s diversity in therapeutic areas and approved drugs and broad \u2060success in clinical trials sets it apart from its peers. However, results from two other upcoming late-stage studies will be a litmus test for long-time CEO Pascal Soriot.<!-- HTML_TAG_END -->  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><!-- HTML_TAG_START -->&#8220;We remain confident in \u200bthe strength \u200bof our pipeline and have more than twenty \u200bhigh-value readouts due over the next \u200c18 months,&#8221; Soriot said in a statement.<!-- HTML_TAG_END -->  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><!-- HTML_TAG_START -->AstraZeneca in 2024 set a target to reach $80 billion in annual revenue by 2030, something JPMorgan analysts said on Monday that the company would be able to achieve.<!-- HTML_TAG_END -->  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><!-- HTML_TAG_START -->2026 OUTLOOK MAINTAINED<!-- HTML_TAG_END -->  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><!-- HTML_TAG_START -->AstraZeneca continues to expect 2026 core earnings per share to increase by a low double-digit percentage at constant currency rates, with total revenue rising \u200cat a rate in the mid-to-high-single digits. It \u200breported sales and profit growth of about 8% and \u200b11%, respectively, last year.<!-- HTML_TAG_END -->  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><!-- HTML_TAG_START -->Core earnings for \u200bthe three months ended June 30 jumped 18% to $2.63 per share, \u200chelped by lower taxes, while total revenue \u200brose 5% to $15.38 billion.<!-- HTML_TAG_END -->  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><!-- HTML_TAG_START -->Analysts \u200bon average were expecting profit of $2.48 per share on sales of $15.39 billion, according to a company-compiled consensus.<!-- HTML_TAG_END -->  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><!-- HTML_TAG_START -->Although the company&#8217;s shares have more than quadrupled in price under \u200bSoriot&#8217;s 14-year tenure, they \u200care down about 8% this year, trailing rival GSK.<!-- HTML_TAG_END -->  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><!-- HTML_TAG_START -->(Reporting by Pushkala Aripaka in \u200bBengaluru and Maggie Fick in London, Raechel Thankam Job and Sri Hari N \u200bS; Editing by Mrigank Dhaniwala, Kirsten Donovan)<!-- HTML_TAG_END -->  <\/p>\n<\/p><\/div>\n<script async=\"async\" data-cfasync=\"false\" src=\"https:\/\/pl30214220.effectivecpmnetwork.com\/9ab3d4df8a7e1a6171e16ddbf732cc19\/invoke.js\"><\/script>\r\n<div id=\"container-9ab3d4df8a7e1a6171e16ddbf732cc19\"><\/div>\r\n\n","protected":false},"excerpt":{"rendered":"<p>July 27 (Reuters) &#8211; AstraZeneca backed its annual and long-term forecasts on Monday after topping second-quarter profit expectations on demand for its cancer and rare disease \u200ctherapies, as the drugmaker sought to quell concerns after recent trial setbacks. Although strong \u200cdemand continues to drive growth against a background of broader pricing pressures, an unexpected trial&#8230;<\/p>\n","protected":false},"author":1,"featured_media":18822,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/s.yimg.com\/lo\/mysterio\/api\/F2C06CB8C9C8B0FCE41FAC3FB1C54DD837FDD4B471A7B1248E1C39DBE5FF3F4C\/subgraphmysterio\/resizefill_w1200_h782;quality_80;format_webp\/https:%2F%2Fmedia.zenfs.com%2Fen%2Freuters.com%2F1672fe08ae755f0f1f8edcc8086b765d","fifu_image_alt":"","footnotes":""},"categories":[18],"tags":[],"class_list":["post-18821","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-real-trending-viral-news"],"brizy_media":[],"_links":{"self":[{"href":"https:\/\/usnews-14267fa.ingress-comporellon.ewp.live\/index.php?rest_route=\/wp\/v2\/posts\/18821","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/usnews-14267fa.ingress-comporellon.ewp.live\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/usnews-14267fa.ingress-comporellon.ewp.live\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/usnews-14267fa.ingress-comporellon.ewp.live\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/usnews-14267fa.ingress-comporellon.ewp.live\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=18821"}],"version-history":[{"count":0,"href":"https:\/\/usnews-14267fa.ingress-comporellon.ewp.live\/index.php?rest_route=\/wp\/v2\/posts\/18821\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/usnews-14267fa.ingress-comporellon.ewp.live\/index.php?rest_route=\/wp\/v2\/media\/18822"}],"wp:attachment":[{"href":"https:\/\/usnews-14267fa.ingress-comporellon.ewp.live\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=18821"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/usnews-14267fa.ingress-comporellon.ewp.live\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=18821"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/usnews-14267fa.ingress-comporellon.ewp.live\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=18821"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}